GlassScriptPhysician profile
Zeeshan Azeem
NPI 1295291409
$774.05
in general payments reported to CMS, 2019-2025
15 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $27.36 · 2022: $63.87 · 2023: $22.91 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $190.13 | 2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $132.99 | 2019-2020 | |
| Vifor Pharma, INC. | $65.49 | 2019 | |
| Travere Therapeutics, INC. | $50.36 | 2025 | |
| Akebia Therapeutics INC | $47.90 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $47.31 | 2019-2025 | Envarsus |
| Astrazeneca Pharmaceuticals LP | $45.96 | 2022 | |
| Horizon Therapeutics Plc | $38.32 | 2019 | |
| Exact Sciences Corporation | $30.43 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $28.55 | 2025 | Prevymis |
| Genzyme Corporation | $24.97 | 2019 | |
| Calliditas Therapeutics US INC. | $22.91 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $17.91 | 2022 | |
| Rockwell Medical, INC. | $15.91 | 2020 | |
| Baxter Healthcare | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Azeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.